ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...
PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback